---
figid: PMC4739416__gr1
figtitle: JAK-STAT signaling contributes to the pathogenesis of MPNs
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4739416
filename: gr1.jpg
figlink: /pmc/articles/PMC4739416/figure/f0005/
number: F1
caption: JAK-STAT signaling contributes to the pathogenesis of MPNs. Unregulated JAK-STAT
  signaling, leading to STAT-mediated hematopoiesis and activation of the PI3K/Akt/mTOR
  pathway, may result from a number of aberrations including point mutations JAK2
  V617F, leading to constitutive activation of JAK2 kinase, and MPL W515L, an activating
  mutation of the thrombopoietin receptor. Number small molecule inhibitors of these
  pathways, including JAK, PI3K, and mTOR inhibitors, are in clinical development.
  Epo, erythropoietin; JAK, Janus kinase; mTOR, mammalian target of rapamycin; PI3K,
  phosphoinositide-3 kinase; STAT, signal transducer and activator of transcription;
  Tpo, thrombopoietin; -i, inhibitor.
papertitle: Evolving Therapeutic Strategies for the Classic Philadelphia-Negative
  Myeloproliferative Neoplasms.
reftext: Jason B. Kaplan, et al. EBioMedicine. 2016 Jan;3:17-25.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9598765
figid_alias: PMC4739416__F1
figtype: Figure
redirect_from: /figures/PMC4739416__F1
ndex: e9e45b4d-de9d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4739416__gr1.html
  '@type': Dataset
  description: JAK-STAT signaling contributes to the pathogenesis of MPNs. Unregulated
    JAK-STAT signaling, leading to STAT-mediated hematopoiesis and activation of the
    PI3K/Akt/mTOR pathway, may result from a number of aberrations including point
    mutations JAK2 V617F, leading to constitutive activation of JAK2 kinase, and MPL
    W515L, an activating mutation of the thrombopoietin receptor. Number small molecule
    inhibitors of these pathways, including JAK, PI3K, and mTOR inhibitors, are in
    clinical development. Epo, erythropoietin; JAK, Janus kinase; mTOR, mammalian
    target of rapamycin; PI3K, phosphoinositide-3 kinase; STAT, signal transducer
    and activator of transcription; Tpo, thrombopoietin; -i, inhibitor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EPO
  - TIMP1
  - EPX
  - TPO
  - THPO
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - AKT1
  - AKT2
  - AKT3
  - MTOR
---
